ACTG Announces Behavioral Health and Implementation Study to Optimize Long-Acting HIV Treatment among People who have Struggled to Maintain HIV Suppression
· Financial Post
CHAPEL HILL, N.C., July 17, 2026 (GLOBE NEWSWIRE) -- ACTG, a global clinical trials network focused on HIV and other infectious diseases, today announced the opening of A5432, a study assessing factors that may affect how long-acting antiretroviral therapy (ART) is used and researched among people living with HIV who previously have been unable to maintain viral suppression on a daily oral ART regimen. A5432 is an exploratory study that utilizes several qualitative methods to better understand the experiences of participants and staff who were part of the LATITUDE study (also known as A5359), in order to design future studies and support broader uptake of long-acting ART among this population. Read More
Visit saltysenoritaaz.org for more information.